Okogen has initiated a phase 2 clinical trial to evaluate the safety and efficacy of OKG-0301 for the treatment of acute adenoviral conjunctivitis.
OKG-0301 is a topical ophthalmic formulation of ranpirnase, which is a targeted ribonuclease with broad-spectrum antiviral properties that is found naturally in tears, according to a company press release.
The multicenter, randomized, placebo-controlled, double-masked RUBY trial will evaluate multiple doses of OKG-0301 in 219 adult patients with acute adenoviral conjunctivitis. Researchers will assess the treatment’s ability to reduce viral
Uncategorized